Trabedersen

DB05697InvestigationalNucleic Acid Based Therapies

Investigated for use/treatment in brain cancer, colorectal cancer, melanoma, and pancreatic cancer.

Mechanism: AP 12009 is an antisense oligodeoxynucleotide that specifically inhibits TGF-beta2. TGF-beta overexpression is a hallmark of various malignant tumors. This is due to the pivotal role of TGF-beta as it regulates key mechanisms of tumor development, namely immunosuppression, metastasis, angiogenesis, and proliferation.
Curator reviewed
Primary indication: Investigated for use/treatment in brain cancer, colorectal cancer, melanoma, and pancreatic cancer.Curator reviewed
Also known as: DNA, D(P-THIO)(C-G-G-C-A-T-G-T-C-T-A-T-T-T-T-G-T-A)
Code names: A-12009 FREE ACID · OT-101

Resolves to

Compound

Targets

What you can answer from here — as of July 17, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

39Drug interactionsStructured to mechanism, not free text

9Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Trabedersen, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.